These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8727310)

  • 21. Low-dose adjuvant interferon for stage III malignant melanoma.
    Inman JL; Russell GB; Savage P; Levine EA
    Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis.
    Ives NJ; Suciu S; Eggermont AMM; Kirkwood J; Lorigan P; Markovic SN; Garbe C; Wheatley K;
    Eur J Cancer; 2017 Sep; 82():171-183. PubMed ID: 28692949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain.
    González-Larriba JL; Serrano S; Alvarez-Mon M; Camacho F; Casado MA; Díaz-Pérez JL; Díaz-Rubio E; Fosbrook L; Guillem V; López-López JJ; Moreno-Nogueira JA; Toribio J
    Eur J Cancer; 2000 Dec; 36(18):2344-52. PubMed ID: 11094308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Melanoma: therapeutic options with recombinant interferons.
    Kirkwood JM; Ernstoff M
    Semin Oncol; 1985 Dec; 12(4 Suppl 5):7-12. PubMed ID: 2417333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
    Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H;
    Lancet Oncol; 2011 Feb; 12(2):144-52. PubMed ID: 21256809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant therapy of melanoma with interferon: lessons of the past decade.
    Ascierto PA; Kirkwood JM
    J Transl Med; 2008 Oct; 6():62. PubMed ID: 18954464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient preferences for adjuvant interferon alfa-2b treatment.
    Kilbridge KL; Weeks JC; Sober AJ; Haluska FG; Slingluff CL; Atkins MB; Sock DE; Kirkwood JM; Nease RF
    J Clin Oncol; 2001 Feb; 19(3):812-23. PubMed ID: 11157035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma.
    Hillner BE
    Eur J Cancer; 1998 Jul; 34 Suppl 3():S18-21. PubMed ID: 9849404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update on PEG-interferon α-2b as adjuvant therapy in melanoma.
    Di Trolio R; Simeone E; Di Lorenzo G; Grimaldi AM; Romano A; Ayala F; Caracò C; Mozzillo N; Ascierto PA
    Anticancer Res; 2012 Sep; 32(9):3901-9. PubMed ID: 22993335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Postsurgical adjuvant therapy for melanoma. Evaluation of a 3-year randomized trial with recombinant interferon-alpha after 3 and 5 years of follow-up.
    Rusciani L; Petraglia S; Alotto M; Calvieri S; Vezzoni G
    Cancer; 1997 Jun; 79(12):2354-60. PubMed ID: 9191523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
    Flaherty LE
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S15-20. PubMed ID: 10685653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
    Eggermont AM
    Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant therapy of malignant melanoma.
    Dickler MN; Coit DG; Meyers ML
    Surg Oncol Clin N Am; 1997 Oct; 6(4):793-812. PubMed ID: 9309094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma.
    Kirkwood JM; Resnick GD; Cole BF
    Semin Oncol; 1997 Feb; 24(1 Suppl 4):S16-23. PubMed ID: 9122729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current status of melanoma treatment with interferon, cytokines and other biologic response modifiers in Japan.
    Ishihara K; Hayasaka K; Yamazaki N
    J Invest Dermatol; 1989 May; 92(5 Suppl):326S-328s. PubMed ID: 2469742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.
    Lienard D; Ewalenko P; Delmotte JJ; Renard N; Lejeune FJ
    J Clin Oncol; 1992 Jan; 10(1):52-60. PubMed ID: 1727926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
    Keilholz U; Goey SH; Punt CJ; Proebstle TM; Salzmann R; Scheibenbogen C; Schadendorf D; Liénard D; Enk A; Dummer R; Hantich B; Geueke AM; Eggermont AM
    J Clin Oncol; 1997 Jul; 15(7):2579-88. PubMed ID: 9215828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma.
    Jonasch E; Kumar UN; Linette GP; Hodi FS; Soiffer RJ; Ryan BF; Sober AJ; Mihm MC; Tsao H; Langley RG; Cosimi BA; Gadd MA; Tanabe KK; Souba W; Haynes HA; Barnhill R; Osteen R; Haluska FG
    Cancer J; 2000; 6(3):139-45. PubMed ID: 10882328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Adjuvant interferon treatment of melanoma].
    Török L
    Magy Onkol; 2003; 47(1):105-7. PubMed ID: 12704462
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II clinical trial of recombinant alpha 2b interferon and 13 cis retinoic acid in patients with metastatic melanoma.
    Rosenthal MA; Oratz R
    Am J Clin Oncol; 1998 Aug; 21(4):352-4. PubMed ID: 9708632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.